A first-in-human study to learn about the safety of BAY 3547926 and how well it works in participants with advanced liver cancer
22262
Phase 1 other active
Quick answer
A first-in-human study to learn about the safety of BAY 3547926 and how well it works in participants with advanced liver cancer for hepatocellular carcinoma (HCC) is a Phase 1 program (other) at Bayer AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bayer AG
- Indication
- hepatocellular carcinoma (HCC)
- Phase
- Phase 1
- Modality
- other
- Status
- active